Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ethicon Breaks New Ground With Articulating Laparoscopic Energy Device

Executive Summary

Ethicon hopes to increase penetration in the advanced energy market with its new ENSEAL G2 Articulating Tissue Sealer, a first-of-its-kind, articulating, laparoscopic energy device designed for use in complex procedures, including colorectal, thoracic, single-site, and cancer surgeries.

You may also be interested in...



Trends In MIS, Part I: Pushing Surgical Boundaries

The market for minimally invasive surgical products continues to grow, driven by increasing demand and advances in laparoscopic technologies and techniques. Medical device manufacturers are developing new and innovative endomechanical and energy devices, as well as improved camera systems, which are allowing surgeons to safely push surgical boundaries and expand the minimally invasive surgery (MIS) approach into more complex surgical procedures than ever before. From a market perspective, manufacturers are driving growth in the MIS product market by targeting underpenetrated and emerging markets, particularly in Asia and Latin America, and by focusing education, sales, and product development efforts on growing clinical areas with good potential for increasing MIS adoption.

Are Regulators Ready For The Robot Era? ChatGPT Weighs In On EU Regulation

Artificial intelligence model’s comments signal the likely start of computer-generated comments to the US FDA’s public notices.

Pink Sheet Podcast: US FDA Loses Gene Therapy Expert, Humira Biosimilars Launch, FDA Allows In-Person Meetings

Pink Sheet reporters and editors consider the impact of FDA Office of Tissues and Advanced Therapies Director Wilson Bryan’s retirement, the launch of Humira biosimilars and its effect on the biologic market, as well as the FDA moving to hybrid meetings with sponsors.

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

MT035603

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel